JP2008531746A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531746A5
JP2008531746A5 JP2008500768A JP2008500768A JP2008531746A5 JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5 JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008500768 A JP2008500768 A JP 2008500768A JP 2008531746 A5 JP2008531746 A5 JP 2008531746A5
Authority
JP
Japan
Prior art keywords
tweak
antibody
receptor
tweak receptor
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008500768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007547 external-priority patent/WO2006096487A2/en
Publication of JP2008531746A publication Critical patent/JP2008531746A/ja
Publication of JP2008531746A5 publication Critical patent/JP2008531746A5/ja
Withdrawn legal-status Critical Current

Links

JP2008500768A 2005-03-07 2006-03-02 Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物 Withdrawn JP2008531746A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65933905P 2005-03-07 2005-03-07
PCT/US2006/007547 WO2006096487A2 (en) 2005-03-07 2006-03-02 Methods and compositions for modulating tweak and fn14 activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013271694A Division JP2014111605A (ja) 2005-03-07 2013-12-27 Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2008531746A JP2008531746A (ja) 2008-08-14
JP2008531746A5 true JP2008531746A5 (enExample) 2009-04-16

Family

ID=36953868

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008500768A Withdrawn JP2008531746A (ja) 2005-03-07 2006-03-02 Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物
JP2013271694A Pending JP2014111605A (ja) 2005-03-07 2013-12-27 Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013271694A Pending JP2014111605A (ja) 2005-03-07 2013-12-27 Ｔｗｅａｋ及びｆｎ１４活性を調節するための方法及び組成物

Country Status (12)

Country Link
US (2) US20080286271A1 (enExample)
EP (1) EP1853312B1 (enExample)
JP (2) JP2008531746A (enExample)
KR (3) KR20130089271A (enExample)
CN (2) CN101171035A (enExample)
AU (1) AU2006220825A1 (enExample)
BR (1) BRPI0608012A2 (enExample)
CA (1) CA2597485A1 (enExample)
IL (1) IL185180A0 (enExample)
RU (1) RU2007137060A (enExample)
WO (1) WO2006096487A2 (enExample)
ZA (1) ZA200707489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004590B1 (ru) 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2008048924A2 (en) * 2006-10-16 2008-04-24 Biogen Idec Ma Inc. Biomarkers of multiple sclerosis
EP2545938A1 (en) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
BR112013007293A2 (pt) * 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
US8609818B2 (en) 2011-03-10 2013-12-17 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN105779576B (zh) * 2014-12-25 2025-01-17 中国人民解放军第四军医大学 人tnfrsf12a基因的用途及其相关药物
US10994017B2 (en) 2016-12-02 2021-05-04 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
TWI843763B (zh) * 2018-10-31 2024-06-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
EA004590B1 (ru) * 1999-01-15 2004-06-24 Байоджен, Инк. Способ блокировки развития, или снижения тяжести, или проявлений заболевания "трасплантат против хозяина"
PT1623990E (pt) * 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6727225B2 (en) * 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP1811838A4 (en) * 2004-11-08 2009-07-22 Univ Maryland TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH
CN101171035A (zh) * 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物

Similar Documents

Publication Publication Date Title
Steeland et al. A new venue of TNF targeting
JP6901493B2 (ja) 抗ｂｃｍａポリペプチド及びタンパク質
JP5837730B2 (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
CA3108915A1 (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CA2558371C (en) Methods of modulating immune responses by modulating tim-1 and tim-4 function
US20030082175A1 (en) April receptor (BCMA) and uses thereof
PL207501B1 (pl) Zastosowanie polipeptydu BCMA oraz przeciwciała skierowanego przeciwko BCMA
KR20200058322A (ko) 항-pd-l1 항체 및 il-7 융합체
KR20190115042A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
Benucci et al. Tumor necrosis factors blocking agents: analogies and differences
CN101675078A (zh) CRIg拮抗剂
US20220288226A1 (en) Methods and compositions to treat autoimmune diseases and cancer
CN116847887A (zh) 治疗自身免疫性疾病和癌症的方法和组合物
US20210395380A1 (en) Variant antibodies that bind ox40
RU2007137060A (ru) Способы и композиции для модуляции активности tweak и fn14
Dörner et al. B-cell targeting: a novel approach to immune intervention today and tomorrow
TW200948377A (en) Affinity matured CRIg variants
TW202336035A (zh) 治療自體免疫疾病及癌症之方法及組成物
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
Soler-Ferran et al. Integrin α4β7 antagonists: activities, mechanisms of action and therapeutic prospects
Scheinberg et al. The potential role of blisibimod for the treatment of systemic lupus erythematosus
HK40000997A (en) Pan-elr+ cxc chemokine antibodies
HK40000997B (en) Pan-elr+ cxc chemokine antibodies
Das Characterisation of heteromers and oligomers in the TNF family of ligands and receptors